Bond Screener
Genmab
LEI 529900MTJPDPE4MHJ122
Organization name
Genmab A/S
Country name
Denmark
Country of registration
Denmark
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
2,500 mln USD
New to Cbonds? · Take a 90-second tour of the platform.
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999.
|
General information
-
Organization nameGenmab A/S
-
Organization statusOperating organization
-
Site
-
IR Site
News
-
Genmab A/S Sponsored ADR (NASDAQ: GMAB) Financial Performance and Investor Sentiment17/02/2026
-
New issues: Genmab issued international bonds (USK3968JAA80, USK3968JAB63) in the amount of USD 1500, USD 1000 mln maturing in 2032, 2033 respectively.21/11/2025
-
Upcoming Issue: Genmab 8Y (Non-callable 3Y)11/11/2025
-
Upcoming Issue: Genmab 7Y (Non-callable 3Y)11/11/2025
-
Genmab A/S Acquires Merus N.V. to Enhance Oncology Portfolio30/09/2025
IFRS/US GAAP reports
| 2026 | |
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
Show more
Hide
Authorization required
You need to request access
